Groupe Hexagone

Groupe Hexagone

Groupe Hexagone was established in Paris as a dedicated fund-of-funds platform for healthcare investing. The firm does not make direct company investments; instead it selects, diligences, and monitors specialist fund managers across the European healthcare continuum. This positions the group as an access vehicle for institutions seeking diversified exposure to a sector where manager selection and scientific literacy heavily influence outcomes. The firm's investment strategy revolves entirely around healthcare and life sciences. Underlying fund commitments span venture capital, growth equity, and buyout strategies, covering biopharma, medical devices, diagnostics, digital health, and healthcare services. Sector-specific knowledge shapes manager selection — the team evaluates GPs on their scientific networks, regulatory expertise, and clinical trial understanding. Confirmed geographic focus is Europe, with an emphasis on Western European innovation clusters including France, Benelux, the DACH region, and the Nordics. The scale of Groupe Hexagone's operations and total capital deployed is not publicly disclosed. The firm maintains a lean structure consistent with a specialist fund-of-funds manager, concentrating resources on fund research, due diligence, and portfolio construction rather than on building a large in-house investment staff. No additional offices or public philanthropic vehicles are reported. Groupe Hexagone's structural differentiator lies in the depth of its sector specialization. By operating exclusively within healthcare, the firm builds domain expertise that a generalist fund-of-funds manager cannot replicate cost-effectively. Its manager-of-managers model shifts the burden of sector specialization from the end allocator to the intermediary — the value proposition is filtering a noisy European health-fund landscape down to a concentrated portfolio of managers with genuine scientific and operational edges. This narrow mandate, while constraining diversification, appeals to allocators who believe healthcare alpha requires dedicated, full-time sector focus.